Great Point Partners LLC Portfolio Holdings

Great Point Partners LLC

  • $127 Million
  • Q3 2025

Great Point Partners LLC has filed its 13F form on November 14, 2025 for Q3 2025 where it was disclosed a total value porftolio of $127 Million distributed in 30 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Amylyx Pharmaceuticals, Inc. with a value of $23.1M, Rezolute, Inc. with a value of $22.8M, Ascendis Pharma A/S with a value of $14.9M, Immunovant, Inc. with a value of $13.8M, and Cytokinetics Inc with a value of $8.24M.

Examining the 13F form we can see an increase of $6.42M in the current position value, from $121M to 127M.

Great Point Partners LLC is based out at Greenwich, CT

Below you can find more details about Great Point Partners LLC portfolio as well as his latest detailed transactions.

Portfolio value $127 Million
Healthcare: $127 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$743M
$23.1 Million 18.2% of portfolio
1,700,000
Q3 2025 Reduced 15.0%
$385M
$22.8 Million 17.94% of portfolio
2,451,809
Q3 2025 Reduced 19.17%
$11.5B
$14.9 Million 11.74% of portfolio
75,000
Q3 2025 New
$3.55B
$13.8 Million 10.83% of portfolio
500,000
Q3 2025 Added 90.71%
$6.17B
$8.24 Million 6.49% of portfolio
150,000
Q2 2025 Reduced 59.46%
$2.49B
$8.03 Million 6.32% of portfolio
200,000
Q2 2025 Reduced 18.46%
$9.91B
$5.23 Million 4.12% of portfolio
80,000
Q3 2025 Reduced 84.0%
$2.52B
$4.93 Million 3.88% of portfolio
103,848
Q2 2025 New
$204M
$4.73 Million 3.72% of portfolio
1,500,000
Q2 2025 New
$18.5M
$4.54 Million 3.58% of portfolio
4,683,711
Q4 2024 Reduced 32.46%
$819M
$3.87 Million 3.05% of portfolio
155,105
Q3 2025 New
$5.19B
$3.7 Million 2.91% of portfolio
113,460
Q3 2025 Reduced 67.58%
$696M
$2.49 Million 1.96% of portfolio
700,000
Q3 2025 New
$266M
$2.42 Million 1.91% of portfolio
796,438
Q3 2025 New
$84.2M
$1.26 Million 0.99% of portfolio
850,000
Q1 2025 Reduced 19.43%
Upstream Bio Inc
-
$0 0.0% of portfolio
-
Q4 2024 New
Unicycive Therapeutics Inc Com New
-
$0 0.0% of portfolio
-
Q2 2025 New
Oruka Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Apogee Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Dbv Technologies S A Sponsored Ads
-
$0 0.0% of portfolio
-
Q3 2025 Added 1.04%
Dianthus Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Eupraxia Pharmaceuticals Inc
-
$0 0.0% of portfolio
-
Q3 2025 New
Jade Biosciences Inc Com New
-
$0 0.0% of portfolio
-
Q3 2025 Added 27.01%
Abivax Sa Sponsored Ads
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 88.39%
Neurogene Inc
-
$0 0.0% of portfolio
-
Q3 2025 Reduced 8.04%
Nektar Therapeutics Com New
-
$0 0.0% of portfolio
-
Q3 2025 New
Zura Bio LTD Class A Ord Shs
-
$0 0.0% of portfolio
-
Q3 2025 Added 20.37%

Summary

  • Portfolio
  • No. of Stocks 30
  • Current Value $127 Million
  • Prior Value $121 Million
  • Filing
  • Period Q3 2025
  • Filing Date November 14, 2025
  • Form Type 13F-HR
  • Activity in Q3 2025
  • New Purchases 10 stocks
  • Additional Purchases 4 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 6 stocks
Track This Portfolio

Track Great Point Partners LLC Portfolio

Follow Great Point Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Great Point Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Great Point Partners LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email